The versatility of HDL: A crucial anti-inflammatory regulator

European Journal of Clinical Investigation

Volumn 40, Issue 12, 2010, Pages 1131-1143

  Säemann, Marcus D ^a   Poglitsch, Marko ^a   Kopecky, Chantal ^a   Haidinger, Michael ^a   Hörl, Walter H ^a   Weichhart, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atheroscleosis; Chronic kidney disease; Dyslipidaemia; Inflammation

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NICOTINIC ACID;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CHRONIC KIDNEY DISEASE; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION; LIPOPROTEINS, HDL;

EID: 78649416898     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2010.02361.x     Document Type: Review

References (102)

1. DeGoma EM, DeGoma RL, Rader DJ. Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 2008;51:2199-211.
2. Rader DJ. Molecular regulation of HDL metabolism and function: implications for novel therapies. J Clin Invest 2006;116:3090-100.
3. Kastelein JJ, Van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30.
4. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discov 2008;7:143-55.
5. Watts GF, Barrett PH, Chan DC. HDL metabolism in context: looking on the bright side. Curr Opin Lipidol 2008;19:395-404.
6. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14.
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
8. Lavie CJ, Milani RV. Shedding light on high-density lipoprotein cholesterol: the post-ILLUMINATE era. J Am Coll Cardiol 2008;51:56-8.
9. Klerkx AH, El Harchaoui K, Van Der Steeg WA, Boekholdt SM, Stroes ES, Kastelein JJ et al. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis. Arterioscler Thromb Vasc Biol 2006;26:706-15.
10. Chiesa G, Sirtori CR. Apolipoprotein A-I(Milano): current perspectives. Curr Opin Lipidol 2003;14:159-63.
11. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002;41:2089-96.
12. Jia Z, Natarajan P, Forte TM, Bielicki JK. Thiol-bearing synthetic peptides retain the antioxidant activity of apolipoproteinA-I(Milano). Biochem Biophys Res Commun 2002;297:206-13.
13. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-300.
14. Van Der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ES et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008;51:634-42.
15. Yan D, Navab M, Bruce C, Fogelman AM, Jiang XC. PLTP deficiency improves the anti-inflammatory properties of HDL and reduces the ability of LDL to induce monocyte chemotactic activity. J Lipid Res 2004;45:1852-8.
16. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC. Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim Biophys Acta 2005;1733:187-91.
17. Briel M, Ferreira-Gonzalez I, You JJ, Karanicolas PJ, Akl EA, Wu P et al. Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis. BMJ 2009;338:b92.
18. Stroes E. Statins and LDL-cholesterol lowering: an overview. Curr Med Res Opin 2005;21:S9-16.
19. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009;58:2711-7.
20. Tsompanidi EM, Brinkmeier MS, Fotiadou EH, Giakoumi SM, Kypreos KE. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2009;208:3-9.
21. Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol 2006;17:258-67.
22. Zannis VI, Koukos G, Drosatos K, Vezeridis A, Zanni EE, Kypreos KE et al. Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med 2008;40(Suppl 1):14-28.
23. Fitzgerald ML, Mujawar Z, Tamehiro N. ABC transporters, atherosclerosis and inflammation. Atherosclerosis 2010; doi:.
24. Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. J Mol Med 2006;84:276-94.
25. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A 1994;91:9607-11.
26. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette transporters A1 and G1, scavenger receptor BI and membrane lipid domains in cholesterol export from macrophages. Curr Opin Lipidol 2006;17:247-57.
27. Oram JF, Lawn RM. ABCA1. The gatekeeper for eliminating excess tissue cholesterol. J Lipid Res 2001;42:1173-9.
28. Jones MK, Catte A, Li L, Segrest JP. Dynamics of activation of lecithin:cholesterol acyltransferase by apolipoprotein A-I. Biochemistry 2009;48:11196-210.
29. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-19.
30. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008;79:360-76.
31. Andersson J, Libby P, Hansson GK. Adaptive immunity and atherosclerosis. Clin Immunol 2010;134:33-46.
32. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis (*). Annu Rev Immunol 2009;27:165-97.
33. Yu R, Yekta B, Vakili L, Gharavi N, Navab M, Marelli D et al. Proatherogenic high-density lipoprotein, vascular inflammation, and mimetic peptides. Curr Atheroscler Rep 2008;10:171-6.
34. Li D, Weng S, Yang B, Zander DS, Saldeen T, Nichols WW et al. Inhibition of arterial thrombus formation by ApoA1 Milano. Arterioscler Thromb Vasc Biol 1999;19:378-83.
35. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W et al. Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003;107:1640-6.
36. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 2007;104:15093-8.
37. Van Lenten BJ, Hama SY, De Beer FC, Stafforini DM, McIntyre TM, Prescott SM et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995;96:2758-67.
38. Reddy S, Hama S, Grijalva V, Hassan K, Mottahedeh R, Hough G et al. Mitogen-activated protein kinase phosphatase 1 activity is necessary for oxidized phospholipids to induce monocyte chemotactic activity in human aortic endothelial cells. J Biol Chem 2001;276:17030-5.
39. Brites FD, Verona J, Schreier LE, Fruchart JC, Castro GR, Wikinski RL. Paraoxonase 1 and platelet-activating factor acetylhydrolase activities in patients with low hdl-cholesterol levels with or without primary hypertriglyceridemia. Arch Med Res 2004;35:235-40.
40. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: metabolism, actions, and therapeutic applications. Shock 2004;21:210-21.
41. De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D et al. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein-associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase. Comparison of adenovirus-mediated human apo A-I gene transfer and human apo A-I transgenesis. Arterioscler Thromb Vasc Biol 2000;20:E68-75.
42. Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW et al. HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 2001;21:481-8.
43. Norata GD, Catapano AL. Molecular mechanisms responsible for the antiinflammatory and protective effect of HDL on the endothelium. Vasc Health Risk Manag 2005;1:119-29.
44. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta2 expression in endothelial cells. Circulation 2005;111:2805-11.
45. Nofer JR, Van Der Giet M, Tolle M, Wolinska I, Von Wnuck Lipinski K, Baba HA et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-81.
46. Gong M, Wilson M, Kelly T, Su W, Dressman J, Kincer J et al. HDL-associated estradiol stimulates endothelial NO synthase and vasodilation in an SR-BI-dependent manner. J Clin Invest 2003;111:1579-87.
47. Mineo C, Shaul PW. HDL stimulation of endothelial nitric oxide synthase: a novel mechanism of HDL action. Trends Cardiovasc Med 2003;13:226-31.
48. Singh NN, Ramji DP. The role of transforming growth factor-beta in atherosclerosis. Cytokine Growth Factor Rev 2006;17:487-99.
49. Nofer JR, Junker R, Pulawski E, Fobker M, Levkau B, Von Eckardstein A et al. High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway. Thromb Haemost 2001;85:730-5.
50. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004;24:871-7.
51. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999;274:33143-7.
52. Park SH, Park JH, Kang JS, Kang YH. Involvement of transcription factors in plasma HDL protection against TNF-alpha-induced vascular cell adhesion molecule-1 expression. Int J Biochem Cell Biol 2003;35:168-82.
53. Galbois A, Thabut D, Tazi KA, Rudler M, Mohammadi MS, Bonnefont-Rousselot D et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology 2009;49:175-84.
54. Guo L, Song Z, Li M, Wu Q, Wang D, Feng H et al. Scavenger Receptor BI Protects against Septic Death through Its Role in Modulating Inflammatory Response. J Biol Chem 2009;284:19826-34.
55. Zhu X, Lee JY, Timmins JM, Brown JM, Boudyguina E, Mulya A et al. Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages. J Biol Chem 2008;283:22930-41.
56. Kockx M, Rye KA, Gaus K, Quinn CM, Wright J, Sloane T et al. Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem 2004;279:25966-77.
57. Murphy AJ, Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SP et al. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071-7.
58. Diederich W, Orso E, Drobnik W, Schmitz G. Apolipoprotein AI and HDL(3) inhibit spreading of primary human monocytes through a mechanism that involves cholesterol depletion and regulation of CDC42. Atherosclerosis 2001;159:313-24.
59. Smythies LE, White CR, Maheshwari A, Palgunachari MN, Anantharamaiah GM, Chaddha M et al. The apolipoprotein A-I mimetic, 4F, alters the function of human monocyte-derived macrophages. Am J Physiol Cell Physiol 2010;298:C1538-48.
60. Dykstra ML, Cherukuri A, Pierce SK. Floating the raft hypothesis for immune receptors: access to rafts controls receptor signaling and trafficking. Traffic 2001;2:160-6.
61. Gombos I, Kiss E, Detre C, Laszlo G, Matko J. Cholesterol and sphingolipids as lipid organizers of the immune cells' plasma membrane: their impact on the functions of MHC molecules, effector T-lymphocytes and T-cell death. Immunol Lett 2006;104:59-69.
62. Kim KD, Lim HY, Lee HG, Yoon DY, Choe YK, Choi I et al. Apolipoprotein A-I induces IL-10 and PGE2 production in human monocytes and inhibits dendritic cell differentiation and maturation. Biochem Biophys Res Commun 2005;338:1126-36.
63. Schwartz GG. Lipid management after acute coronary syndrome. Curr Opin Lipidol 2007;18:626-32.
64. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-56.
65. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007;297:1675-82.
66. Meyer P, Nigam A, Marcil M, Tardif JC. The therapeutic potential of high-density lipoprotein mimetic agents in coronary artery disease. Curr Atheroscler Rep 2009;11:329-33.
67. Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17:2034-47.
68. Morena M, Cristol JP, Dantoine T, Carbonneau MA, Descomps B, Canaud B. Protective effects of high-density lipoprotein against oxidative stress are impaired in haemodialysis patients. Nephrol Dial Transplant 2000;15:389-95.
69. Jurek A, Turyna B, Kubit P, Klein A. LDL susceptibility to oxidation and HDL antioxidant capacity in patients with renal failure. Clin Biochem 2006;39:19-27.
70. Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009;153:77-85.
71. Kalantar-Zadeh K, Kopple JD, Kamranpour N, Fogelman AM, Navab M. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int 2007;72:1149-56.
72. Krane V, Drechsler C, Wanner C. Dyslipidemia, inflammation and dialysis outcomes: what we know now. Curr Opin Nephrol Hypertens 2006;15:566-70.
73. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-72.
74. Van Linthout S, Spillmann F, Schultheiss HP, Tschope C. High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders. Curr Pharm Des 2010;16:1504-16.
75. Connelly PW, Zinman B, Maguire GF, Mamakeesick M, Harris SB, Hegele RA et al. Association of the novel cardiovascular risk factors paraoxonase 1 and cystatin C in type 2 diabetes. J Lipid Res 2009;50:1216-22.
76. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may Be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999;19:2226-33.
77. Hedrick CC, Thorpe SR, Fu MX, Harper CM, Yoo J, Kim SM et al. Glycation impairs high-density lipoprotein function. Diabetologia 2000;43:312-20.
78. Dodani S, Kaur R, Reddy S, Reed GL, Navab M, George V. Can dysfunctional HDL explain high coronary artery disease risk in South Asians? Int J Cardiol 2008;129:125-32.
79. Mehra MR, Uber PA, Lavie CJ, Milani RV, Park MH, Ventura HO. High-density lipoprotein cholesterol levels and prognosis in advanced heart failure. J Heart Lung Transplant 2009;28:876-80.
80. Sviridov D, Chin-Dusting J, Nestel P, Kingwell B, Hoang A, Olchawa B et al. Elevated HDL cholesterol is functionally ineffective in cardiac transplant recipients: evidence for impaired reverse cholesterol transport. Transplantation 2006;81:361-6.
81. Navab M, Hama SY, Hough GP, Subbanagounder G, Reddy ST, Fogelman AM. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001;42:1308-17.
82. Tan KC, Chow WS, Lam JC, Lam B, Wong WK, Tam S et al. HDL dysfunction in obstructive sleep apnea. Atherosclerosis 2006;184:377-82.
83. Van Leuven SI, Hezemans R, Levels JH, Snoek S, Stokkers PC, Hovingh GK et al. Enhanced atherogenesis and altered high density lipoprotein in patients with Crohn's disease. J Lipid Res 2007;48:2640-6.
84. Hahn BH, Grossman J, Ansell BJ, Skaggs BJ, McMahon M. Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2008;10:213.
85. McMahon M, Grossman J, FitzGerald J, Dahlin-Lee E, Wallace DJ, Thong BY et al. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:2541-9.
86. Liang MH, Mandl LA, Costenbader K, Fox E, Karlson E. Atherosclerotic vascular disease in systemic lupus erythematosus. J Natl Med Assoc 2002;94:813-9.
87. Charles-Schoeman C, Khanna D, Furst DE, McMahon M, Reddy ST, Fogelman AM et al. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study. J Rheumatol 2007;34:1459-64.
88. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum 2009;60:2870-9.
89. Navab M, Anantharamaiah GM, Hama S, Garber DW, Chaddha M, Hough G et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002;105:290-2.
90. Navab M, Anantharamaiah GM, Hama S, Hough G, Reddy ST, Frank JS et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005;25:1426-32.
91. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 2007;8:201-12.
92. Li X, Chyu KY, Faria Neto JR, Yano J, Nathwani N, Ferreira C et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004;110:1701-5.
93. Navab M, Anantharamaiah GM, Reddy ST, Hama S, Hough G, Grijalva VR et al. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 2004;109:3215-20.
94. Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L et al. Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 2002;106:1127-32.
95. Vaziri ND, Moradi H, Pahl MV, Fogelman AM, Navab M. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int 2009;76:437-44.
96. Rezaee F, Casetta B, Levels JH, Speijer D, Meijers JC. Proteomic analysis of high-density lipoprotein. Proteomics 2006;6:721-30.
97. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010;30:156-63.
98. Green PS, Vaisar T, Pennathur S, Kulstad JJ, Moore AB, Marcovina S et al. Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation 2008;118:1259-67.
99. Stahlman M, Davidsson P, Kanmert I, Rosengren B, Boren J, Fagerberg B et al. Proteomics and lipids of lipoproteins isolated at low salt concentrations in D2O/sucrose or in KBr. J Lipid Res 2008;49:481-90.
100. McGillicuddy FC, De La Llera Moya M, Hinkle CC, Joshi MR, Chiquoine EH, Billheimer JT et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135-45.
101. Clay MA, Pyle DH, Rye KA, Vadas MA, Gamble JR, Barter PJ. Time sequence of the inhibition of endothelial adhesion molecule expression by reconstituted high density lipoproteins. Atherosclerosis 2001;157:23-9.
102. Ulevitch RJ, Johnston AR, Weinstein DB. New function for high density lipoproteins. Isolation and characterization of a bacterial lipopolysaccharide-high density lipoprotein complex formed in rabbit plasma. J Clin Invest 1981;67:827-37.